Cartography Biosciences Co-Founder and Chief Executive Officer Kevin Parker, Ph.D., Earns Spot on Endpoints News’ 20 Under 40 List

—Annual list spotlights the young biopharma leaders making their mark on the industry—

SOUTH SAN FRANCISCO, May 30, 2023 – Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas, today announced that Kevin Parker, Ph.D., co-founder and CEO of Cartography Biosciences, has been selected as a 2023 Endpoints 20 Under 40 honorree.

Each year, Endpoints profiles the next generation of biotech leaders who are already making an impact on the industry, with the potential to make an even bigger one in their long careers ahead. Honorees on the 2023 list were selected for their ability to stand out in their field, make a difference today and make a bigger one tomorrow.

“I’m honored to be recognized alongside such an esteemed collection of leaders in the biopharma space,” said Kevin Parker, Ph.D., co-founder and CEO of Cartography Biosciences. “Collaborating with Cartography’s team of world-class scientists is what pushes me to think outside the box and challenge how we approach target identification for immuno-oncology treatments. Together, we’re building the future of cell-specific cancer therapies. I look forward to what’s next for Cartography as we work to develop therapeutics as precise as their targets – for every patient with cancer.”

The full Endpoints 20 Under 40 list can be found here.

About Cartography Biosciences

Cartography Biosciences is focused on developing tumor-selective therapeutics that are based on a unique genomics and computational platform. Cartography’s platform integrates data from proprietary sample sourcing relationships, an industry-leading comprehensive reference atlas, and our target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. To learn more about Cartography and our mission to treat every patient with cancer, visit cartography.bio and follow us on LinkedIn and Twitter @cartographybio.

Media Contact:
MacDougall Advisors
Karen Sharma